The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > June 26, 2025
Daily News
June 26, 2025
- DPP’s Tamura Renews Call to Scrap Off-Year Drug Price Cuts, Urges Protection of On-Patent Prices
June 26, 2025
- Japan Begins FY2026 Drug Pricing Reform Talks; Responses to Inflation, High-Cost Therapies on Agenda
June 26, 2025
- ASKA Launches Japan PIII of Relugolix Combo for Endometriosis
June 26, 2025
- Japan Approves Crysvita Prefilled Syringe: Kyowa Kirin
June 26, 2025
- SanBio Pushes Back Shipment Approval Timeline for Cell Therapy Akuugo
June 26, 2025
- Chuikyo OKs Drug Price Survey Plan for FY2026 Revision
June 26, 2025
- Study Group Urges Japan to Accelerate Genomic Medicine Rollout
June 26, 2025
- Takeda Zeros in on US Successor Ahead of 2026 CEO Transition
June 26, 2025
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…